Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab

Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care...

Descripción completa

Detalles Bibliográficos
Autores principales: Horiuchi, Hiroshi, Sasaki, Hiroaki, Miyazaki, Kazuhito, Miyata, Nobuyuki, Yoshimura, Yukihiro, Tachikawa, Natsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612813/
https://www.ncbi.nlm.nih.gov/pubmed/34887178
http://dx.doi.org/10.1016/j.jiac.2021.11.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612813/
https://www.ncbi.nlm.nih.gov/pubmed/34887178
http://dx.doi.org/10.1016/j.jiac.2021.11.018

Ejemplares similares